Karyopharm Q1 revenue $35.1M, net loss $22.4M; Phase 3 endometrial trial enrollment complete

Karyopharm Therapeutics Inc.

U.S. XPOVIO net product revenue $29.2M (up from $21.1M YoY) on lower gross-to-net adjustments.
Net loss $22.4M ($1.02 basic loss per share) vs $23.5M loss in Q1 2025.
Cash $91.2M as of Mar 31, 2026; expects liquidity to fund operations into late Q3 2026.
Completed Phase 3 XPORT-EC-042 enrollment in endometrial cancer; topline data expected mid-2026.
Phase 3 SENTRY myelofibrosis results accepted for late-breaking oral at ASCO on June 2.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Karyopharm Therapeutics Inc. reported Full-Year 2026 results: revenue Company Reaffirms Full-Year 2026 Total Revenue Guidance of $130 Million to $150 Million Including U.S. XPOVIO Net Produc. Guidance reaffirmed.

Period: Full-Year 2026
Revenue: Company Reaffirms Full-Year 2026 Total Revenue Guidance of $130 Million to $150 Million Including U.S. XPOVIO Net Produc
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

Company Reaffirms Full-Year 2026 Total Revenue Guidance of $130 Million to $150 Million Including U.S. XPOVIO Net Product Revenue Guidance of $115 Million to $130 Million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.97

Karyopharm Therapeutics Inc. reported first quarter of 2026 results: revenue Total Revenue was $35.1 Million. Guidance reaffirmed.

Period: first quarter of 2026
Revenue: Total Revenue was $35.1 Million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Total Revenue was $35.1 Million and U.S. XPOVIO® (selinexor) Net Product Revenue was $29.2 Million for the First Quarter of 2026

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Karyopharm Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-222808

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.